StockData

Liminatus Pharma, Inc. (LIMN) stock

LIMNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as LIMNW
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 2/30
$2.81+0.13 (+4.85%)

Close on Nov 19, 2026Market cap $188.72MP/E –Yield –

Liminatus Pharma free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Liminatus Pharma's free cash flow for the twelve months ending Dec 31, 2025 was -$9.98M. For fiscal 2025 it was -$9.98M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$9.98M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025-$386.85K–

More Liminatus Pharma figures

See a number that looks wrong?